Drug profile · INN
levetiracetam
APO-LEVETIRACETAM
levetiracetam (APO-LEVETIRACETAM) is a synaptic vesicle glycoprotein 2a modulator. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — levetiracetam
- US status
- approved
- Class
- Nervous system (N03)
- Route
- ORAL
- Patents
- 1
- Programs
- 12
- Data quality
- 0.89
Quick answer
levetiracetam (APO-LEVETIRACETAM) is a synaptic vesicle glycoprotein 2a modulator. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Synaptic vesicle glycoprotein 2A modulator
Primary target: Synaptic vesicle glycoprotein 2A
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is levetiracetam?
levetiracetam (APO-LEVETIRACETAM) is a synaptic vesicle glycoprotein 2a modulator. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for levetiracetam?
APO-LEVETIRACETAM is a marketed brand name for levetiracetam. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of levetiracetam?
levetiracetam has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.